美女免费一级视频在线观看

The Ozempic shortage is over and the Ozempic era is here.

Novo Nordisk launched its latest campaign – My Ozempic Era – just a few weeks after the Food and Drug Administration took semaglutide, the active ingredient in its popular GLP-1s Ozempic and Wegovy, off its shortages list.

My Ozempic Era represents another push forward by the drugmaker in the diabetes and obesity treatment space. 

Earlier this week, the company unveiled NovoCare Pharmacy, offering home shipments of the popular GLP-1 Wegovy at $499 per month for cash-paying patients.

This campaign features the testimony of three patient ambassadors living with type 2 diabetes who pair Ozempic with diet and exercise. The goal is to encourage others living with the condition to have their own “Ozempic eras.”

Tivonnia Harvey, head of Novo’s diabetes therapeutic area, said the team was initially inspired to create the campaign when the FDA expanded Ozempic’s indication to treat chronic kidney disease for type 2 diabetes patients in January.

She said that regulatory greenlight provided a perfect opportunity for Novo to think about what this new campaign needed to look like.

“We knew that it all needs to start with the patients, so it was critical for us to use real patient ambassadors that are suffering with type 2 diabetes and bring their stories to life,” Harvey said. 

Among the patient ambassadors are country musicians Michael and Tanya Trotter, critically-acclaimed chef Franklin Becker and entrepreneur and hair stylist Maria. 

According to Harvey, the team chose all three because of how they manage living with diabetes while pursuing their creative passions.

Videos of each patient ambassador shows them singing the catchy “Oh, oh, oh Ozempic” jingle in various backgrounds – whether onstage, in the kitchen or at the hair salon.

“Throughout all of this, [the campaign] shows how they have taken control of their type 2 diabetes and how they haven’t allowed that to stop them from living their lives and doing the things they love to do,” Harvey said.

By launching My Ozempic Era, Harvey said Novo wants people living with type 2 diabetes to see themselves in the campaign and feel empowered to have conversations with their healthcare providers about whether these injections are right for them.

GLP-1s have been the subject of unprecedented demand since coming on to the market in the past few years, so much so that off-label use caused prolonged shortages impacting manufacturers like Novo and rival Eli Lilly.

Throughout the GLP-1 shortages, patients struggled to pick up their prescriptions and many had to pause or halt treatment.

However, the dynamics in the obesity treatment space has started to change over the past few months, with Lilly’s tirzepatide coming off the FDA shortage list in December.

Last month, the FDA removed semaglutide from the shortages list after nearly three years of demand outpacing supply. 

One sector that took off during the scarcity challenge were compounding pharmacies, which offered compounded versions of GLP-1 drugs.

Novo and Lilly have fought back – through advertising and in the courts – against these compounders as well as telehealth companies that connect patients with the products. 

With Novo’s shortage concerns shelved for now and legal rulings in favor of drugmakers over compounders, Harvey emphasized that the Danish pharma giant is “fully stocked at all doses” for both Ozempic and Wegovy.

In the initial stage of the campaign, My Ozempic Era will roll out via television, social media and digital platforms. Harvey said the company will soon unveil a Spanish language version to target Hispanic populations.

Both Hispanic and Black populations are predominantly impacted by type 2 diabetes as well as cardiovascular disease, Harvey said, so the campaign aims to resonate with both of those groups.